Scrip
>>Business

Soriot's Future And MYSTIC Data To Dominate AstraZeneca's 2Q

24 Jul 2017

Impending critical data for AstraZeneca's PD-1 inhibitor Imfinzi, which is expected to be the backbone of the company's growing cancer immunotherapy portfolio, and speculation around CEO Pascal Soriot's recent trip to Israel, where it is rumored he met with a rival pharma company about its vacant chief exec role, will be hot topics during the company's second-quarter earnings call this week.

Sphere — AstraZeneca’s future in oncology hangs on MYSTIC; but is Soriot in or out? • Source: Shutterstock

AstraZeneca PLC's second-quarter performance is likely to be hit by ongoing drug pricing pressures, generic erosion and lower than expected externalization revenue. These factors will nevertheless be overshadowed by imminent data from the Phase III MYSTIC trial and ongoing speculation around CEO Pascal Soriot's recent visit to Israel.

AstraZeneca's 2Q earnings, to be reported on July 27, will highlight growing pressures on the company's more established drugs and focus on pricing strategies for its diabetes and respiratory franchises.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

02 Jun 2025

• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.